Entero Therapeutics, Stock Current Valuation
| ENTO Stock | 0.47 0.01 2.17% |
Valuation analysis of Entero Therapeutics, helps investors to measure Entero Therapeutics,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Entero Therapeutics,'s Enterprise Value Over EBITDA is very stable compared to the past year. As of the 29th of November 2024, Enterprise Value Multiple is likely to grow to 0.11, though Enterprise Value is likely to grow to (1.5 M). Fundamental drivers impacting Entero Therapeutics,'s valuation include:
Price Book 0.0684 | Enterprise Value 66.3 M | Enterprise Value Ebitda (0.10) |
Undervalued
Today
Please note that Entero Therapeutics,'s price fluctuation is risky at this time. Calculation of the real value of Entero Therapeutics, is based on 3 months time horizon. Increasing Entero Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Entero Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Entero Stock. However, Entero Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.47 | Real 9.33 | Target 36.0 | Hype 0.38 |
The intrinsic value of Entero Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Entero Therapeutics,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Entero Therapeutics, helps investors to forecast how Entero stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Entero Therapeutics, more accurately as focusing exclusively on Entero Therapeutics,'s fundamentals will not take into account other important factors: Entero Therapeutics, Company Current Valuation Analysis
Entero Therapeutics,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Entero Therapeutics, Current Valuation | 66.34 M |
Most of Entero Therapeutics,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Entero Therapeutics, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Entero Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Entero Therapeutics, is extremely important. It helps to project a fair market value of Entero Stock properly, considering its historical fundamentals such as Current Valuation. Since Entero Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Entero Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Entero Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Entero Therapeutics, has a Current Valuation of 66.34 M. This is 99.54% lower than that of the Biotechnology sector and 98.57% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.6% higher than that of the company.
Entero Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entero Therapeutics,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entero Therapeutics, could also be used in its relative valuation, which is a method of valuing Entero Therapeutics, by comparing valuation metrics of similar companies.Entero Therapeutics, is currently under evaluation in current valuation category among its peers.
Entero Therapeutics, Current Valuation Drivers
We derive many important indicators used in calculating different scores of Entero Therapeutics, from analyzing Entero Therapeutics,'s financial statements. These drivers represent accounts that assess Entero Therapeutics,'s ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Entero Therapeutics,'s important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 23.3M | 27.6M | 12.9M | 4.4M | 1.3M | 1.2M | |
| Enterprise Value | 23.3M | 22.2M | 5.7M | 3.9M | (1.6M) | (1.5M) |
Entero Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 66.34 M | ||||
| Shares Outstanding | 3.25 M | ||||
| Shares Owned By Insiders | 7.20 % | ||||
| Shares Owned By Institutions | 5.98 % | ||||
| Number Of Shares Shorted | 152.93 K | ||||
| Price To Book | 0.07 X | ||||
| EBITDA | (15.74 M) | ||||
| Net Income | (15.79 M) | ||||
| Total Debt | 826.84 K | ||||
| Book Value Per Share | 7.99 X | ||||
| Cash Flow From Operations | (12.38 M) | ||||
| Short Ratio | 0.06 X | ||||
| Earnings Per Share | (11.04) X | ||||
| Target Price | 36.0 | ||||
| Beta | 1.37 | ||||
| Market Capitalization | 1.11 M | ||||
| Total Asset | 6.88 M | ||||
| Retained Earnings | (184.33 M) | ||||
| Working Capital | 1.82 M | ||||
| Net Asset | 6.88 M |
About Entero Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Entero Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entero Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entero Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Entero Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving together with Entero Stock
Moving against Entero Stock
| 0.64 | ELAN | Elanco Animal Health | PairCorr |
| 0.62 | HLN | Haleon plc | PairCorr |
| 0.6 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.51 | ZTS | Zoetis Inc | PairCorr |
| 0.42 | TAK | Takeda Pharmaceutical | PairCorr |
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Entero Therapeutics, Piotroski F Score and Entero Therapeutics, Altman Z Score analysis. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.